Screener
Charles River Laboratories CRL Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Retained earnings | 1,372,295 | 1,388,620 |
| Treasury stock, at cost, 1,822 and zero shares, as of June 27, 2026 and December 27, 2025, respectively | (323,189) | — |
| Accumulated other comprehensive loss | (195,989) | (171,783) |
| Total Charles River Laboratories International, Inc. equity | 2,839,636 | 3,164,630 |
| Nonredeemable noncontrolling interest | 6,354 | 5,301 |
| Total equity | 2,845,990 | 3,169,931 |
| Total liabilities, redeemable noncontrolling interests and equity | $7,532,145 | $7,135,422 |
| See Notes to Unaudited Condensed Consolidated Financial Statements. |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's total equity?
- Charles River Laboratories (CRL) reported total equity of $2.84B in Q2 2026.
- How has Charles River Laboratories's total equity changed year-over-year?
- Charles River Laboratories's total equity decreased by 15.3% year-over-year, from $3.35B to $2.84B.
- What is the long-term trend for Charles River Laboratories's total equity?
- Over 5 years (2020 to 2025), Charles River Laboratories's total equity has grown at a 8.4% compound annual growth rate (CAGR), from $2.11B to $3.16B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Charles River Laboratories's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude